{"topic":{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain":"medicine","description":"Semaglutide, tirzepatide and next-generation incretin agonists; obesity, diabetes, cardiovascular, renal, liver and neuropsychiatric outcomes.","keywords":["GLP-1"],"paper_count":230,"latest_published":"2026-10-27","url":"https://space-kitty.com/topics/glp1-metabolic","api_url":"https://space-kitty.com/api/v1/topics/glp1-metabolic"},"dossier":{"slug":"glp1-metabolic","topic":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","summary":"Covers semaglutide, tirzepatide, the new oral GLP-1 agonists and next-generation triple-agonist and amylin-combination drugs, with their effects on weight, diabetes, cardiovascular, kidney, heart-failure, liver, sleep-apnea, joint and brain outcomes as of October 2026. The central takeaway: the field has moved from proving weight loss to proving organ protection. Placebo-adjusted mean weight loss at the top doses of pivotal trials in adults without diabetes now ranges from about 9 percentage points (oral orforglipron) to about 21 (retatrutide, not yet approved), and the main open questions are durability after stopping, lean-mass and rare safety signals, cost and access, and how much of the benefit is independent of weight loss.","version":1,"published_at":"2026-10-29","updated_at":"2026-10-29","stats":{"words":5487,"citations":100,"claims":36,"timeline":18,"benchmarks":12,"open_problems":8,"key_papers":14,"glossary":12},"verification":{"status":"verified","method":"Independent AI fact-check against cited sources: evidence-pack check of 36 claims + 124 contexts (including 18 timeline and 12 benchmark rows), 17 web checks (batch PubMed abstracts for all 89 DOI records, ClinicalTrials.gov records for 9 trials, one PMC record, agency/company announcements and trade press for regulatory and topline claims); automated citation resolution","claims_checked":36,"contexts_checked":124,"web_checks":17,"issues_fixed":31,"verified_at":"2026-10-29","notes":["Thyroid cancer: replaced \"inconclusive because events are rare\" with the 2026 review's mixed evidence (rodent-based boxed warning; three trial meta-analyses reporting an increase); pancreatic-cancer statement kept on the 2021 safety review.","SURPASS-CVOT: removed the unverifiable claim that all-cause death sat outside multiplicity-controlled testing; added the verified HR 0.84 (95% CI 0.75-0.94) with a caution.","Executive summary: SUMMIT benefit attributed to worsening-heart-failure events; cross-trial efficacy headline softened; STEP 1 extension labelled exploratory (n=327); SURMOUNT-OSA population and REDEFINE 4 estimand specified; GI adverse-event context added.","Citations re-pointed: Nature Reviews Drug Discovery review moved from a mouse-circuit claim to the lean-mass discussion; energy-intake claim now cites the two physiology reviews; OASIS 1 and OASIS 4 added for the 25-50 mg oral doses.","Company and regulatory events (FDA approvals of oral semaglutide 25 mg in Dec 2025 and orforglipron in Apr 2026, EMA NAION conclusion in Jun 2025, CMS BALANCE/Bridge changes, Nov 2025 USD 245 Medicare price, generic launches, REDEFINE 4 and TRIUMPH toplines, Q1 2027 retatrutide filing plan) were checked against agency/company announcements and trade press and stay attributed in the text, since no DOI/NCT/PMID exists for them.","Removed or softened unsupported details: CMS date (April to spring 2026, sources disagree), evoke topline date, China data-protection rationale, AMPLIFY-1 start (not yet recruiting), older-adult and heart-failure-subtype statements not in the cited abstracts, \"about four years\" follow-up.","Consistency and safety context: SUMMIT and SURMOUNT-1 3-year benchmark years changed from 2025 to 2024 to match records and timeline; estimand-gap example corrected to 2.8 and 3.3 points; comparator or severity context added to cholelithiasis, GI, gastric-content, dysesthesia and EMA NAION statements; type 1 diabetes sentence reworded so it does not read as dosing advice.","No new citation ids added; all 100 cited keys resolve to evidence-pack records. The dossier has no in-file disclaimer; the site-level not-medical-advice notice applies."]},"ai_assisted":true,"price":{"usd":"0.20","protocol":"x402","network":"eip155:84532","asset":"USDC"},"url":"https://space-kitty.com/dossiers/glp1-metabolic","preview_url":"https://space-kitty.com/api/v1/dossiers/glp1-metabolic/preview","purchase_url":"https://space-kitty.com/api/v1/dossiers/glp1-metabolic"},"top_papers":[{"id":"doi:10.1056/nejmoa2032183","kind":"article","title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","authors":["John P.H. Wilding","Rachel Louise Batterham","Salvatore Calanna","Melanie Jane Davies","Luc F. Van Gaal","Ildiko Lingvay"],"author_count":14,"year":2021,"published":"2021-02-10","venue":"New England Journal of Medicine","cited_by":5188,"doi":"10.1056/nejmoa2032183","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa2032183","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa2032183"},{"id":"doi:10.1056/nejmoa2307563","kind":"article","title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","authors":["Abraham Michael Lincoff","Kirstine Brown‐Frandsen","Helen Martina Colhoun","John Eric Deanfield","Scott S. Emerson","Sille Esbjerg"],"author_count":16,"year":2023,"published":"2023-11-11","venue":"New England Journal of Medicine","cited_by":3220,"doi":"10.1056/nejmoa2307563","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa2307563","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa2307563"},{"id":"doi:10.1056/nejmoa2306963","kind":"article","title":"Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity","authors":["Mikhail Kosiborod","Steen Zabell Abildstrom","Barry A. Borlaug","Javed Butler","Søren Rasmussen","Melanie Jane Davies"],"author_count":31,"year":2023,"published":"2023-08-25","venue":"New England Journal of Medicine","cited_by":1661,"doi":"10.1056/nejmoa2306963","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa2306963","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa2306963"},{"id":"doi:10.1111/dom.14725","kind":"article","title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension","authors":["John P.H. Wilding","Rachel Louise Batterham","Melanie Jane Davies","Luc F. Van Gaal","Kristian Kandler","Katerina Konakli"],"author_count":15,"year":2022,"published":"2022-04-19","venue":"Diabetes Obesity and Metabolism","cited_by":1120,"doi":"10.1111/dom.14725","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1111/dom.14725","archive_url":"https://space-kitty.com/papers/doi:10.1111/dom.14725"},{"id":"doi:10.1001/jama.2021.3224","kind":"article","title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity","authors":["Domenica Rubino","Niclas Abrahamsson","Melanie Jane Davies","Dan Hesse","Frank L. Greenway","Camilla Jensen"],"author_count":88,"year":2021,"published":"2021-03-23","venue":"JAMA","cited_by":1443,"doi":"10.1001/jama.2021.3224","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1001/jama.2021.3224","archive_url":"https://space-kitty.com/papers/doi:10.1001/jama.2021.3224"},{"id":"doi:10.1016/s0140-6736(21)00213-0","kind":"article","title":"Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","authors":["Melanie Jane Davies","Louise Færch","Ole Kleist Jeppesen","Arash Pakseresht","Sue D. Pedersen","Leigh Perreault"],"author_count":11,"year":2021,"published":"2021-03-01","venue":"The Lancet","cited_by":1419,"doi":"10.1016/s0140-6736(21)00213-0","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/s0140-6736(21)00213-0","archive_url":"https://space-kitty.com/papers/doi:10.1016/s0140-6736(21)00213-0"},{"id":"doi:10.1038/s41591-022-02026-4","kind":"article","title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","authors":["William Timothy Garvey","Rachel Louise Batterham","Meena Bhatta","Silvio Buscemi","Louise N. Christensen","Juan P. Frías"],"author_count":12,"year":2022,"published":"2022-10-01","venue":"Nature Medicine","cited_by":867,"doi":"10.1038/s41591-022-02026-4","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41591-022-02026-4","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41591-022-02026-4"},{"id":"doi:10.1056/nejmoa2416394","kind":"article","title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","authors":["Louis J. Aronne","Deborah Bade Horn","Carel Wynand le Roux","Wayne Ho","Beverly L. Falcón","Elisa Gomez Valderas"],"author_count":11,"year":2025,"published":"2025-05-11","venue":"New England Journal of Medicine","cited_by":626,"doi":"10.1056/nejmoa2416394","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa2416394","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa2416394"},{"id":"doi:10.1001/jama.2021.1831","kind":"article","title":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity","authors":["Thomas A. Wadden","Timothy Silleck Bailey","Liana K. Billings","Melanie Jane Davies","Juan P. Frías","Anna Koroleva"],"author_count":13,"year":2021,"published":"2021-02-24","venue":"JAMA","cited_by":1113,"doi":"10.1001/jama.2021.1831","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1001/jama.2021.1831","archive_url":"https://space-kitty.com/papers/doi:10.1001/jama.2021.1831"},{"id":"doi:10.1056/nejmoa2313917","kind":"article","title":"Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes","authors":["Mikhail Kosiborod","Mark Colquhoun Petrie","Barry A. Borlaug","Javed Butler","Melanie Jane Davies","G. Kees Hovingh"],"author_count":32,"year":2024,"published":"2024-03-28","venue":"New England Journal of Medicine","cited_by":753,"doi":"10.1056/nejmoa2313917","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa2313917","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa2313917"},{"id":"doi:10.3389/fendo.2019.00155","kind":"review","title":"The Discovery and Development of Liraglutide and Semaglutide","authors":["Lotte Bjerre Knudsen","Jesper F. Lau"],"author_count":2,"year":2019,"published":"2019-04-12","venue":"Frontiers in Endocrinology","cited_by":969,"doi":"10.3389/fendo.2019.00155","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3389/fendo.2019.00155","archive_url":"https://space-kitty.com/papers/doi:10.3389/fendo.2019.00155"},{"id":"doi:10.1001/jama.2021.23619","kind":"article","title":"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes","authors":["Domenica M. Rubino","Frank L. Greenway","Usman Khalid","Patrick M. O’Neil","Julio Rosenstock","Rasmus Sørrig"],"author_count":23,"year":2022,"published":"2022-01-11","venue":"JAMA","cited_by":994,"doi":"10.1001/jama.2021.23619","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1001/jama.2021.23619","archive_url":"https://space-kitty.com/papers/doi:10.1001/jama.2021.23619"},{"id":"doi:10.1001/jama.2023.19897","kind":"review","title":"Obesity Management in Adults","authors":["Arielle Elmaleh-Sachs","Jessica L. Schwartz","Carolyn T. Bramante","Jacinda Mawson Nicklas","Kimberly Anne Gudzune","Melanie R Jay"],"author_count":6,"year":2023,"published":"2023-11-28","venue":"JAMA","cited_by":756,"doi":"10.1001/jama.2023.19897","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1001/jama.2023.19897","archive_url":"https://space-kitty.com/papers/doi:10.1001/jama.2023.19897"},{"id":"doi:10.1001/jamanetworkopen.2024.57349","kind":"article","title":"Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity","authors":["Patricia J. Rodriguez","Vincent Zhang","Samuel Gratzl","Duy Do","Brianna M Goodwin Cartwright","Charlotte Baker"],"author_count":9,"year":2025,"published":"2025-01-31","venue":"JAMA Network Open","cited_by":370,"doi":"10.1001/jamanetworkopen.2024.57349","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1001/jamanetworkopen.2024.57349","archive_url":"https://space-kitty.com/papers/doi:10.1001/jamanetworkopen.2024.57349"},{"id":"doi:10.1038/s41591-024-02996-7","kind":"article","title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","authors":["Donna H. Ryan","Ildiko Lingvay","John Eric Deanfield","Steven E. Kahn","Eric Barros","Bartolome G. Burguera"],"author_count":20,"year":2024,"published":"2024-05-13","venue":"Nature Medicine","cited_by":346,"doi":"10.1038/s41591-024-02996-7","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1038/s41591-024-02996-7","archive_url":"https://space-kitty.com/papers/doi:10.1038/s41591-024-02996-7"}],"newest_papers":[{"id":"doi:10.1111/dom.71428","kind":"review","title":"GLP-1-Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection","authors":["Rossatto T","de Andrade Oliveira R","Cardoso AM"],"author_count":3,"year":2026,"published":"2026-10-27","venue":"Diabetes, obesity & metabolism","cited_by":0,"doi":"10.1111/dom.71428","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1111/dom.71428","archive_url":"https://space-kitty.com/papers/doi:10.1111/dom.71428"},{"id":"doi:10.1056/nejmoa2611477","kind":"article","title":"Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea","authors":["Ronald R. Grunstein","Virend Kristen Somers","Ali Azarbarzin","Atul Malhotra","Scott A. Sands","Brendan P. Lucey"],"author_count":12,"year":2026,"published":"2026-10-20","venue":"New England Journal of Medicine","cited_by":0,"doi":"10.1056/nejmoa2611477","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa2611477","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa2611477"},{"id":"nct:NCT07881432","kind":"trial","title":"A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes","authors":["Eli Lilly and Company"],"author_count":1,"year":2026,"published":"2026-10-19","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07881432","source_url":"https://clinicaltrials.gov/study/NCT07881432","archive_url":"https://space-kitty.com/papers/nct:NCT07881432"},{"id":"pmc:PMC13697276","kind":"article","title":"Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial","authors":["Almandoz J","Miras A","Blüher M","Orozco Del Pino P","Mojdami D","Batterham R"],"author_count":9,"year":2026,"published":"2026-10-14","venue":"Obesity pillars","cited_by":0,"doi":null,"arxiv_id":null,"nct_id":null,"source_url":"https://europepmc.org/article/PMC/PMC13697276","archive_url":"https://space-kitty.com/papers/pmc:PMC13697276"},{"id":"doi:10.1016/j.obpill.2026.100344","kind":"article","title":"12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study","authors":["Angelopoulos N","Fousteris E","Zianni D","Androulakis I","Paparodis R","Florakis D"],"author_count":17,"year":2026,"published":"2026-10-12","venue":"Obesity pillars","cited_by":0,"doi":"10.1016/j.obpill.2026.100344","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.obpill.2026.100344","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.obpill.2026.100344"},{"id":"doi:10.3390/medsci14060652","kind":"review","title":"Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review","authors":["Gupta AK","Teasell EM","Magalhães RF","Mirmirani P","Piguet V"],"author_count":5,"year":2026,"published":"2026-10-09","venue":"Medical sciences (Basel, Switzerland)","cited_by":0,"doi":"10.3390/medsci14060652","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.3390/medsci14060652","archive_url":"https://space-kitty.com/papers/doi:10.3390/medsci14060652"},{"id":"doi:10.1016/j.ejphar.2026.179406","kind":"review","title":"GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases","authors":["Koceva E","Moll GN"],"author_count":2,"year":2026,"published":"2026-10-08","venue":"European journal of pharmacology","cited_by":0,"doi":"10.1016/j.ejphar.2026.179406","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.ejphar.2026.179406","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.ejphar.2026.179406"},{"id":"doi:10.1016/j.ejphar.2026.179418","kind":"article","title":"Tirzepatide alleviates hepatic steatosis and inflammation in MASLD partly through suppression of macrophage Dectin-1/Syk/NF-κB signaling","authors":["He Y","Ma T","Xing H","Cao X","Song F","Pan Y"],"author_count":7,"year":2026,"published":"2026-10-08","venue":"European journal of pharmacology","cited_by":0,"doi":"10.1016/j.ejphar.2026.179418","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1016/j.ejphar.2026.179418","archive_url":"https://space-kitty.com/papers/doi:10.1016/j.ejphar.2026.179418"},{"id":"nct:NCT07866066","kind":"trial","title":"Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes","authors":["Amgen"],"author_count":1,"year":2026,"published":"2026-10-08","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07866066","source_url":"https://clinicaltrials.gov/study/NCT07866066","archive_url":"https://space-kitty.com/papers/nct:NCT07866066"},{"id":"doi:10.1002/oby.70311","kind":"article","title":"The Conventional Cost-Effectiveness and Distributional Cost-Effectiveness of Semaglutide for Obesity Treatment","authors":["Kulkarni NS","Hutton D","Rhyan C","McCullough JS","Greenlee M","Pandya A"],"author_count":6,"year":2026,"published":"2026-10-07","venue":"Obesity (Silver Spring, Md.)","cited_by":0,"doi":"10.1002/oby.70311","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1002/oby.70311","archive_url":"https://space-kitty.com/papers/doi:10.1002/oby.70311"}],"related_topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","api_url":"https://space-kitty.com/api/v1/topics/cancer-immunotherapy"},{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","api_url":"https://space-kitty.com/api/v1/topics/mrna-cancer-vaccines"},{"slug":"gene-editing-therapies","name":"CRISPR & Gene-Editing Therapies","api_url":"https://space-kitty.com/api/v1/topics/gene-editing-therapies"},{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","api_url":"https://space-kitty.com/api/v1/topics/gene-cell-therapy"},{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","api_url":"https://space-kitty.com/api/v1/topics/neurodegeneration"},{"slug":"aging-longevity","name":"Biology of Aging & Longevity","api_url":"https://space-kitty.com/api/v1/topics/aging-longevity"},{"slug":"infectious-disease-amr","name":"Infectious Disease, Vaccines & Antimicrobial Resistance","api_url":"https://space-kitty.com/api/v1/topics/infectious-disease-amr"},{"slug":"ai-medicine","name":"AI in Clinical Medicine","api_url":"https://space-kitty.com/api/v1/topics/ai-medicine"},{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","api_url":"https://space-kitty.com/api/v1/topics/cardiovascular-innovation"}],"premium":{"dossier":{"url":"https://space-kitty.com/api/v1/dossiers/glp1-metabolic","price_usd":"0.20"},"research_pack":{"url":"https://space-kitty.com/api/v1/topics/glp1-metabolic/pack","price_usd":"0.20"}},"more":"https://space-kitty.com/api/v1/topics/glp1-metabolic/papers?sort=top&limit=100"}